Regenerative therapy in cardiology by human amnion-derived immunotolerant cells in allogeneic combination

人羊膜来源的免疫耐受细胞同种异体组合在心脏病学中的再生治疗

• 批准号: 23791861
• 负责人: NISHIYAMA Hiroko
• 金额: $ 2.58万
• 依托单位: National Research Institute for Child Health and Development
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2013
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23791861/
• 关键词: 産科学; 羊膜; アログラフト; 再生医療; 羊膜細胞; 心筋; 間葉系細胞; 免疫寛容

At present, the definitive therapy to patients with severe heart failure is only heart transplantation. However, lack of donor organs is indeed a social problem in the world. We have previously established isolation system of mesenchymal stem cells from amnion, and showed availability of amnion-derived cells as a transplantable biomaterial. Once availability of amnion-derived cells from the viewpoint of regenerative therapy is established, cell source problem must be solved. In this study, we showed long-term survival of amnion-derived cells and elucidate mechanism of in vivo immune tolerance.

目前，对严重心力衰竭患者的最终治疗方法是心脏移植。然而，捐赠器官的缺乏确实是世界上的一个社会问题。我们已经建立了羊膜间充质干细胞的分离体系，并展示了羊膜来源细胞作为一种可移植的生物材料的可行性。一旦从再生治疗的角度确定了羊膜来源细胞的可用性，细胞来源问题就必须得到解决。在这项研究中，我们展示了羊膜来源细胞的长期存活，并阐明了体内免疫耐受的机制。